Imedx Information Services Private Limited - Due diligence report

A 360° intelligence report on Imedx: trust score, financial health, credit view, compliance, directors, growth and distress signals - genera…

2005-02-22 Amberpet, Telangana Active Unlisted Active Compliant
Share
Connect MCP
II Imedx Information Services Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Imedx — 360° Intelligence Report

Generated from MCA filings & public records
51/100
Trust Score
Moderate

Imedx is assessed as Moderate with a Trust Score of 51/100. Imedx is an active private limited indian non-government company incorporated in 2005, operating in the Information Technology sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 05 Aug 2026 from the latest processed filings. Imedx Information Services Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Neutral
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
51/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
58/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 9 satisfied (6.08 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Oriental Bank Of Commerce4 48.0 cr
Hdfc Bank Limited4 48.0 cr
Kotak Mahindra Bank Limited1 48.0 cr
Compliance Score: 58/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • Litigation present in 1 court forum(s).
  • 2 auditor resignation(s) filed - latest: Sudit K. Parekh & Co on 2016-02-23.
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
KSHATRAPATI BALI KARAN SINGH 01234567 Director 01/04/2018 6 yrs Approved
JOSEPH RAYMOND D’ANGELO 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2018)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Imedx Inc
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Imedx Inc Holding Company 74.00%

Key managerial personnel: KSHATRAPATI BALI KARAN SINGH (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 30
Growth signals & trust indicators
Operating for 21+ years.
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
Statutory filings appear overdue.
Compliance score is weak (58/100).
2 auditor resignation(s) on record - review the stated reasons.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence48/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment36/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view30/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Jun 2023
Last AGM held
Annual general meeting
29 Jun 2023
Director ceased
JOSEPH RAYMOND D’ANGELO
31 Mar 2023
Latest balance sheet
Filed with ROC
10 Oct 2022
Director appointed
JOSEPH RAYMOND D’ANGELO (Director)
09 Aug 2022
Director ceased
KSHATRAPATI BALI KARAN SINGH
17 Jun 2022
Director ceased
MICHAEL WILLIAM RUBEL
Director ceased
MICHAEL JEFFREY FOSTER
Director ceased
CHRISTOPHER SHANNON FOLEY
Director ceased
JON EDWARD TROPSA
28 Jun 2021
Charge satisfied
Hdfc Bank Limited
25 Sep 2017
Director ceased
BOBBA VENKATADRI
04 Apr 2017
Director ceased
RAMESH ALUR
31 Mar 2017
Share transfer (FY 2017)
2.00000000 shares to FOLEY SHANNON
27 Oct 2016
Director appointed
KSHATRAPATI BALI KARAN SINGH (Managing Director)
29 Jul 2016
Director ceased
VENKAT SHARMA
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
2 active director(s) / partner(s); board looks stable and experienced.
All 9 registered charge(s) stand satisfied - past borrowings repaid.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
4 overseas direct investment(s) (ODI) on record - international footprint.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Mahendra Labs Private Limited U33125KA1984PTC006459 Bangalore, Karnataka, India
Sunetra Eye Centre Private Limited U85100MH2012PTC467183 New Delhi, Delhi, India
Seeds Of Innocence U85191UP2013PTC058685 Ghaziabad, Uttar Pradesh, India
Medilink Enterprises Private Limited U33110TN2008PTC066576 Adyar, Tamil Nadu, India
Advani Olickal Healthcare Services Private Limited U93090MH2010PTC199529 Mumbai, Maharashtra, India
Raj Jindal Hospital And Research Centre Private Limited U85110RJ2005PTC020103 Jaipur, Rajasthan, India
Matrix Imaging Solutions India Private Limited U74900KA2009PTC051330 Bangalore North, Karnataka, India
Acclin Path Labs India Private Limited U85100TG2019PTC136291 Hyderabad, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Imedx before audits and certifications: compliance score 58/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Imedx: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Imedx - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 51/100, distress signals and MSME payment-delay disclosures - know whether Imedx pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Imedx - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Imedx an active company?

Imedx has MCA status “Active” with a compliance score of 58/100 (Moderate).

Is Imedx financially healthy?

Imedx has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Imedx?

Its overall Trust Score is 51/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Imedx?

The ultimate holding entity is Imedx Inc. 2 active director(s) are on record.

Does Imedx have loans or charges against its assets?

No open charges - all 9 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Imedx up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 58/100 (Moderate).

Is it risky to lend to Imedx?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.